{"id":36159,"date":"2025-10-16T12:11:08","date_gmt":"2025-10-16T05:11:08","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=36159"},"modified":"2025-10-16T12:11:08","modified_gmt":"2025-10-16T05:11:08","slug":"gene-solutions-brings-insights-on-advances-in-mrd-and-multi-omics-technologies-to-the-singapore-society-of-oncology-annual-scientific-meeting-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=36159","title":{"rendered":"Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), <a href=\"https:\/\/genesolutions.com\/\" target=\"_blank\" rel=\"nofollow\">Gene Solutions<\/a> showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across <span class=\"xn-location\">Asia-Pacific<\/span>, reinforcing <span class=\"xn-location\">Singapore&#8217;s<\/span> role as a hub for innovation and global collaboration.<\/p>\n<p>The symposium, <i>&#8220;Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,&#8221; <\/i>gathered leading oncologists and molecular biology experts to explore how ctDNA-MRD and multi-omics support clinicians and researchers in <span class=\"xn-location\">Singapore<\/span> and across the <span class=\"xn-location\">Asia-Pacific<\/span>.<\/p>\n<p><b>Key Scientific Highlights<\/b><\/p>\n<p>MRD assays analyze circulating tumor DNA (ctDNA) in the blood to monitor cancer at the molecular level. Experts discussed how this approach may:<\/p>\n<ul type=\"disc\">\n<li><b>Detect recurrence earlier <\/b>\u2013 Identify molecular signals before imaging, enabling timely decisions<\/li>\n<li><b>Assess surgical outcomes<\/b> \u2013 Determine residual cancer post-surgery, guiding follow-up strategies.<\/li>\n<li><b>Track treatment response<\/b> \u2013 Monitor ctDNA clearance to review treatment strategies in real time.<\/li>\n<li><b>Support risk stratification<\/b>\u2013 Identify high-risk patients for tailored treatment, potentially reducing unnecessary toxicity for low-risk patients.<\/li>\n<\/ul>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2794568\/Panel_Discussion.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2794568\/Panel_Discussion.jpg?p=medium600\" title=\"Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.\" alt=\"Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.\" \/><\/a><br \/><span>Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.<\/span><\/p>\n<\/div>\n<p><b>Gene Solutions&#8217; Scientific Approach<\/b><\/p>\n<p>Unlike single-modality tests, Gene Solutions&#8217; platform integrates <b>DNA, RNA, and AI-enhanced multi-omics signals<\/b> for comprehensive tumor profiling and personalized ctDNA monitoring. This multi-omics approach has the potential to improve ctDNA sensitivity, detect complex gene fusions, and predict primary tumor locations \u2014 supporting deeper insights for more informed, personalized treatment decisions.<\/p>\n<p class=\"prntal\">Recent studies published in JCO Oncology Advances<sup>1<\/sup> and Nature&#8217;s npj Breast Cancer<sup>2<\/sup>\u00a0highlight the potential of ctDNA-based MRD testing to predict early recurrence and contribute to affordable monitoring strategies in real-world contexts. Through its CAP-accredited <span class=\"xn-location\">Singapore<\/span> laboratory and global operations network, Gene Solutions fosters scientific collaboration to advance genomic research and precision oncology across the <span class=\"xn-location\">Asia-Pacific<\/span>.<\/p>\n<p class=\"prntal\"><b>A Call for Collaboration<\/b><\/p>\n<p><span>Ida Deleskog Lindstroem, Global Medical Affairs Director, emphasized: &#8220;Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively.\u00a0We invite\u00a0oncologists, researchers, and healthcare partners across <span class=\"xn-location\">Asia-Pacific<\/span> to collaborate in advancing these technologies, fostering data-driven, personalized care that aims to improve patient outcomes across diverse healthcare systems.&#8221;<\/span><\/p>\n<p><b>Read<\/b><b>\u00a0more about symposium highlight at: <\/b><a href=\"https:\/\/genesolutions.com\/news\/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore\" target=\"_blank\" rel=\"nofollow\">https:\/\/genesolutions.com\/news\/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore<\/a><\/p>\n<p><b>About Gene Solutions<\/b><\/p>\n<p><b>Gene Solutions<\/b> is a multinational biotechnology company at the forefront of genetic testing and research innovation across the <span class=\"xn-location\">Asia-Pacific<\/span> region. Leveraging <b>Next-Generation Sequencing (NGS)<\/b> and <b>Artificial Intelligence<\/b>, the company offers a comprehensive portfolio of advanced solutions, including:<\/p>\n<ul type=\"disc\">\n<li><b>Next-generation non-invasive prenatal testing (NIPT)<\/b>\u00a0for fetal and maternal health.<\/li>\n<li><b>Multi-cancer screening<\/b> using clinically validated multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.<\/li>\n<li><b>Comprehensive genomic and transcriptomic profiling<\/b>\u00a0combined with <b>ctDNA-based m<\/b><b>olecular<\/b><b>\u00a0residual disease (MRD) monitoring<\/b> to guide precision treatment and track disease progression.<\/li>\n<\/ul>\n<p>With over <b>two million genetic tests delivered<\/b>, Gene Solutions is recognized for its proprietary research, <b>CAP-accredited laboratories<\/b>, and contributions to advancing precision medicine through <b>clinical studies, technology development, and regional collaborations<\/b>.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Disclaimer: For healthcare professionals and researchers only. Not intended as medical advice. Claims based on published studies; ctDNA-MRD and multi-omics approaches requires further clinical validation.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>References<\/p>\n<p>(1)\u00a0 Hoang, V.-A.N. et al. (2025) &#8216;Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,&#8217; JCO Oncology Advances, Volume 2. DOI: 10.1200\/OA-24-00084<\/p>\n<p>(2)\u00a0 Nguyen, S. T., <span class=\"xn-person\">Nguyen Hoang<\/span>, V. A., <span class=\"xn-person\">Nguyen Trieu<\/span>, V., et al. Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. npj Breast Cancer 11, 58 (2025). DOI: 10.1038\/s41523-025-00778-z<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), <a href=\"https:\/\/genesolutions.com\/\" target=\"_blank\" rel=\"nofollow\">Gene Solutions<\/a> showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across <span class=\"xn-location\">Asia-Pacific<\/span>, reinforcing <span class=\"xn-location\">Singapore&#8217;s<\/span> role as a hub for innovation and global collaboration.<\/p>\n<p>The symposium, <i>&#8220;Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,&#8221; <\/i>gathered leading oncologists and molecular biology experts to explore how ctDNA-MRD and multi-omics support clinicians and researchers in <span class=\"xn-location\">Singapore<\/span> and across the <span class=\"xn-location\">Asia-Pacific<\/span>.<\/p>\n<p><b>Key Scientific Highlights<\/b><\/p>\n<p>MRD assays analyze circulating tumor DNA (ctDNA) in the blood to monitor cancer at the molecular level. Experts discussed how this approach may:<\/p>\n<ul type=\"disc\">\n<li><b>Detect recurrence earlier <\/b>\u2013 Identify molecular signals before imaging, enabling timely decisions<\/li>\n<li><b>Assess surgical outcomes<\/b> \u2013 Determine residual cancer post-surgery, guiding follow-up strategies.<\/li>\n<li><b>Track treatment response<\/b> \u2013 Monitor ctDNA clearance to review treatment strategies in real time.<\/li>\n<li><b>Support risk stratification<\/b>\u2013 Identify high-risk patients for tailored treatment, potentially reducing unnecessary toxicity for low-risk patients.<\/li>\n<\/ul>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2794568\/Panel_Discussion.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2794568\/Panel_Discussion.jpg?p=medium600\" title=\"Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.\" alt=\"Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.\" \/><\/a><br \/><span>Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer\/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.<\/span><\/p>\n<\/div>\n<p><b>Gene Solutions&#8217; Scientific Approach<\/b><\/p>\n<p>Unlike single-modality tests, Gene Solutions&#8217; platform integrates <b>DNA, RNA, and AI-enhanced multi-omics signals<\/b> for comprehensive tumor profiling and personalized ctDNA monitoring. This multi-omics approach has the potential to improve ctDNA sensitivity, detect complex gene fusions, and predict primary tumor locations \u2014 supporting deeper insights for more informed, personalized treatment decisions.<\/p>\n<p class=\"prntal\">Recent studies published in JCO Oncology Advances<sup>1<\/sup> and Nature&#8217;s npj Breast Cancer<sup>2<\/sup>\u00a0highlight the potential of ctDNA-based MRD testing to predict early recurrence and contribute to affordable monitoring strategies in real-world contexts. Through its CAP-accredited <span class=\"xn-location\">Singapore<\/span> laboratory and global operations network, Gene Solutions fosters scientific collaboration to advance genomic research and precision oncology across the <span class=\"xn-location\">Asia-Pacific<\/span>.<\/p>\n<p class=\"prntal\"><b>A Call for Collaboration<\/b><\/p>\n<p><span>Ida Deleskog Lindstroem, Global Medical Affairs Director, emphasized: &#8220;Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively.\u00a0We invite\u00a0oncologists, researchers, and healthcare partners across <span class=\"xn-location\">Asia-Pacific<\/span> to collaborate in advancing these technologies, fostering data-driven, personalized care that aims to improve patient outcomes across diverse healthcare systems.&#8221;<\/span><\/p>\n<p><b>Read<\/b><b>\u00a0more about symposium highlight at: <\/b><a href=\"https:\/\/genesolutions.com\/news\/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore\" target=\"_blank\" rel=\"nofollow\">https:\/\/genesolutions.com\/news\/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore<\/a><\/p>\n<p><b>About Gene Solutions<\/b><\/p>\n<p><b>Gene Solutions<\/b> is a multinational biotechnology company at the forefront of genetic testing and research innovation across the <span class=\"xn-location\">Asia-Pacific<\/span> region. Leveraging <b>Next-Generation Sequencing (NGS)<\/b> and <b>Artificial Intelligence<\/b>, the company offers a comprehensive portfolio of advanced solutions, including:<\/p>\n<ul type=\"disc\">\n<li><b>Next-generation non-invasive prenatal testing (NIPT)<\/b>\u00a0for fetal and maternal health.<\/li>\n<li><b>Multi-cancer screening<\/b> using clinically validated multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.<\/li>\n<li><b>Comprehensive genomic and transcriptomic profiling<\/b>\u00a0combined with <b>ctDNA-based m<\/b><b>olecular<\/b><b>\u00a0residual disease (MRD) monitoring<\/b> to guide precision treatment and track disease progression.<\/li>\n<\/ul>\n<p>With over <b>two million genetic tests delivered<\/b>, Gene Solutions is recognized for its proprietary research, <b>CAP-accredited laboratories<\/b>, and contributions to advancing precision medicine through <b>clinical studies, technology development, and regional collaborations<\/b>.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Disclaimer: For healthcare professionals and researchers only. Not intended as medical advice. Claims based on published studies; ctDNA-MRD and multi-omics approaches requires further clinical validation.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>References<\/p>\n<p>(1)\u00a0 Hoang, V.-A.N. et al. (2025) &#8216;Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,&#8217; JCO Oncology Advances, Volume 2. DOI: 10.1200\/OA-24-00084<\/p>\n<p>(2)\u00a0 Nguyen, S. T., <span class=\"xn-person\">Nguyen Hoang<\/span>, V. A., <span class=\"xn-person\">Nguyen Trieu<\/span>, V., et al. Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. npj Breast Cancer 11, 58 (2025). DOI: 10.1038\/s41523-025-00778-z<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-36159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36159"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36159\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}